Lipanthyl (Fenofibrate)
Fibrate medication for lowering triglycerides and cholesterol
Lipanthyl contains the active ingredient fenofibrate and belongs to a group of medicines called fibrates. It is used to lower high levels of fats (lipids) in the blood, particularly triglycerides and cholesterol. Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPAR-α), which regulates lipid metabolism. It is prescribed alongside a low-fat diet, exercise, and weight management, and may be used in combination with statin therapy when statins alone do not provide adequate lipid control.
Quick Facts
Key Takeaways
- Lipanthyl (fenofibrate) is a fibrate medication that primarily lowers triglycerides and raises HDL cholesterol, and is used in combination with lifestyle changes
- Always take Lipanthyl with a meal — absorption is significantly reduced on an empty stomach, making the medication less effective
- Do not take fenofibrate if you have severe liver disease, severe kidney disease, gallbladder disease, or a history of pancreatitis unrelated to high blood fats
- Combining fenofibrate with statins increases the risk of serious muscle problems (rhabdomyolysis) — report any unexplained muscle pain immediately
- Fenofibrate must not be used during pregnancy or while breastfeeding, and is not recommended for patients under 18 years of age
What Is Lipanthyl and What Is It Used For?
Quick Answer: Lipanthyl contains fenofibrate, a fibrate medication used to lower elevated triglycerides and cholesterol in the blood. It is prescribed alongside dietary modifications, exercise, and weight management to treat dyslipidaemia (abnormal blood fat levels).
Lipanthyl belongs to a class of lipid-modifying agents known as fibrates. Fibrates have been used in clinical practice for over five decades to manage lipid disorders, and fenofibrate is one of the most widely prescribed fibrates globally. The primary therapeutic benefit of fenofibrate lies in its ability to substantially reduce triglyceride levels (by 20–50%) while modestly increasing high-density lipoprotein (HDL) cholesterol (by 10–20%), often referred to as “good cholesterol.” It also has a moderate effect on lowering low-density lipoprotein (LDL) cholesterol.
The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) include fibrates such as fenofibrate as a treatment option in their 2019 guidelines for the management of dyslipidaemias. The American Heart Association (AHA) and the National Lipid Association (NLA) also recognise fenofibrate as a therapeutic option, particularly for patients with severe hypertriglyceridaemia or mixed dyslipidaemia who do not achieve adequate control with statin therapy alone.
Fenofibrate is a prodrug that is rapidly converted to its active form, fenofibric acid, after ingestion. Fenofibric acid acts by activating peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that regulates the transcription of genes involved in lipid metabolism. This activation increases the production and activity of lipoprotein lipase (the enzyme that breaks down triglyceride-rich lipoproteins), reduces the production of apolipoprotein C-III (which inhibits triglyceride clearance), stimulates the synthesis of apolipoproteins A-I and A-II (the main protein components of HDL), and promotes fatty acid oxidation in the liver, reducing hepatic production of very-low-density lipoprotein (VLDL).
Approved Uses
Fenofibrate is indicated for the following conditions when dietary and other non-pharmacological measures (e.g., exercise, weight loss) have proven insufficient:
- Severe hypertriglyceridaemia: Treatment of markedly elevated triglyceride levels, with or without low HDL cholesterol. Severe hypertriglyceridaemia (above 500 mg/dL or 5.6 mmol/L) carries a significant risk of acute pancreatitis, making triglyceride reduction clinically important
- Mixed dyslipidaemia (hyperlipidaemia): Reduction of both elevated triglycerides and total cholesterol, particularly in patients with type IIa, IIb, III, IV, and V hyperlipoproteinaemia according to the Fredrickson classification
- Adjunctive therapy with statins: Fenofibrate may be added to statin therapy when a statin alone does not achieve satisfactory lipid control, especially when residual hypertriglyceridaemia and low HDL persist despite optimal statin dosing. This combination should be prescribed under careful medical supervision
Triglycerides are the most common type of fat in the blood. While the body needs triglycerides for energy, persistently elevated levels are associated with an increased risk of cardiovascular disease, including coronary artery disease, stroke, and peripheral arterial disease. Very high triglycerides (above 500 mg/dL) also significantly raise the risk of acute pancreatitis, a potentially life-threatening inflammation of the pancreas. The ESC/EAS guidelines identify triglyceride levels above 150 mg/dL (1.7 mmol/L) as a cardiovascular risk factor.
Mechanism of Action
Fenofibrate exerts its lipid-modifying effects through several complementary pathways mediated by PPAR-α activation:
- Triglyceride reduction: Increases lipoprotein lipase activity (enhancing the breakdown of triglyceride-rich VLDL particles) and suppresses apolipoprotein C-III expression, which normally inhibits triglyceride clearance
- HDL elevation: Stimulates the production of apolipoproteins A-I and A-II, the structural proteins of HDL particles, thereby promoting reverse cholesterol transport (the process by which excess cholesterol is returned from tissues to the liver for excretion)
- LDL modification: Shifts the LDL particle profile from small, dense (more atherogenic) LDL toward larger, more buoyant (less atherogenic) LDL particles. Promotes LDL receptor expression, increasing LDL clearance from the bloodstream
- Anti-inflammatory effects: Reduces markers of vascular inflammation, including C-reactive protein (CRP) and fibrinogen, which may contribute to cardiovascular benefit beyond lipid lowering
- Uric acid reduction: Fenofibrate has a unique uricosuric effect (increases renal excretion of uric acid), which can lower serum uric acid levels — a property not shared by most other lipid-modifying agents
What Should You Know Before Taking Lipanthyl?
Quick Answer: Before starting Lipanthyl, your doctor should assess your liver function, kidney function, and current medications. Fenofibrate is contraindicated in severe liver, kidney, or gallbladder disease and in patients with a history of pancreatitis not caused by high triglycerides.
Fenofibrate is generally well tolerated when used appropriately, but there are several important medical conditions, warnings, and precautions that both patients and healthcare providers must be aware of before initiating treatment. A thorough medical evaluation, including baseline liver function tests, kidney function tests, and a complete lipid panel, should precede the start of fenofibrate therapy.
Contraindications
Do not take Lipanthyl (fenofibrate) if any of the following apply:
- Allergy to fenofibrate or any of the other ingredients in the formulation (listed in the Composition section)
- Prior photosensitivity or phototoxic reaction during treatment with other fibrates or ketoprofen (a non-steroidal anti-inflammatory drug). If you have previously experienced an allergic reaction or skin damage from sunlight or UV light while taking another fibrate or ketoprofen, you must not use fenofibrate
- Severe liver disease: Including cirrhosis, active hepatitis, or unexplained persistent elevation of liver enzymes (transaminases)
- Severe kidney disease: Estimated glomerular filtration rate (eGFR) below 15 mL/min or patients requiring dialysis
- Gallbladder disease: Including cholelithiasis (gallstones) or cholecystitis (gallbladder inflammation). Fenofibrate increases cholesterol excretion into bile, which can exacerbate gallbladder conditions
- Pancreatitis: Acute or chronic pancreatitis that is not caused by severe hypertriglyceridaemia. If pancreatitis is a consequence of high triglycerides, fenofibrate may still be considered under careful supervision
Warnings and Precautions
Speak to your doctor, pharmacist, or nurse before taking Lipanthyl if any of the following apply:
Stop taking Lipanthyl and contact your doctor immediately if you experience unexplained muscle cramps, tenderness, pain, or weakness, especially if accompanied by fever or general malaise. Fenofibrate can cause muscle inflammation (myositis) and, in rare cases, rhabdomyolysis (breakdown of muscle tissue that can lead to acute kidney failure and death). The risk is higher in patients over 70 years of age, those with kidney impairment, those with hypothyroidism (underactive thyroid), those with a personal or family history of hereditary muscle disorders, those who consume large amounts of alcohol, and those taking statins concurrently. Your doctor may perform blood tests (creatine kinase levels) before and during treatment to monitor muscle health.
Liver function: Your doctor should perform liver function tests (transaminases) before starting treatment and periodically during therapy (typically at 3 months and then every 6–12 months). If liver enzymes rise to more than 3 times the upper limit of normal, fenofibrate should be discontinued. Signs of possible liver inflammation (hepatitis) include yellowing of the skin or eyes (jaundice), dark urine, abdominal pain, and unexplained fatigue.
Kidney function: Fenofibrate may cause a reversible increase in serum creatinine levels, which does not usually indicate actual kidney damage but rather an effect on creatinine production. However, patients with pre-existing kidney impairment require dose reduction or may be unable to use fenofibrate. Your doctor will monitor your kidney function during treatment and adjust the dose accordingly.
Hypothyroidism: An underactive thyroid gland (hypothyroidism) is a common cause of secondary hyperlipidaemia. This condition should be adequately treated before starting fenofibrate. Additionally, hypothyroidism increases the risk of muscle-related side effects.
Gallstones: Fenofibrate increases the excretion of cholesterol into bile, which can potentially promote gallstone formation. Although this risk is considered low with fenofibrate compared to older fibrates (such as clofibrate), patients should be monitored for signs of gallbladder disease.
Venous thromboembolism (VTE): Cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported with fenofibrate use, although a causal relationship has not been definitively established. Patients with risk factors for VTE should be monitored. Seek immediate medical attention if you develop pain, redness, or swelling in a leg, or sudden chest pain and shortness of breath.
Pregnancy and Breastfeeding
Pregnancy: Lipanthyl must not be taken during pregnancy. There are insufficient data on the use of fenofibrate in pregnant women, and animal studies have shown potential reproductive toxicity. If you are pregnant, think you may be pregnant, or are planning to become pregnant, do not take this medication and inform your doctor immediately.
Breastfeeding: It is not known whether fenofibrate or its metabolites are excreted into human breast milk. Due to the potential risk to the infant, Lipanthyl must not be used during breastfeeding.
Fertility: Animal studies have not shown effects on fertility at therapeutic doses. However, no human data are available.
Driving and Operating Machinery
Lipanthyl has no known effect on the ability to drive or operate machinery. Fenofibrate does not cause sedation, dizziness, or other impairments that would affect driving safety.
Important Information About Excipients
Lactose: Lipanthyl 200 mg capsules contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Sodium: This medicine contains less than 1 mmol (23 mg) sodium per capsule, meaning it is essentially sodium-free.
How Does Lipanthyl Interact with Other Drugs?
Quick Answer: Fenofibrate has clinically significant interactions with anticoagulants (warfarin), statins, ciclosporin, and certain diabetes medications. The most important interaction is with statins, as the combination increases the risk of serious muscle damage (rhabdomyolysis).
Drug interactions are an important consideration when prescribing fenofibrate. Because fibrates and several other medication classes affect overlapping metabolic pathways, co-administration can lead to enhanced toxicity or altered drug effectiveness. Always inform your doctor or pharmacist about all medications, supplements, and herbal products you are taking before starting Lipanthyl.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments, additional monitoring, or avoidance of the combination:
| Medication | Effect of Interaction | Clinical Action |
|---|---|---|
| Warfarin and other coumarin anticoagulants | Fenofibrate displaces warfarin from plasma protein binding sites and enhances its anticoagulant effect, increasing bleeding risk | Reduce warfarin dose by approximately one-third at initiation; monitor INR frequently and adjust dose accordingly |
| Statins (simvastatin, atorvastatin, rosuvastatin, pravastatin, fluvastatin) | Increased risk of myopathy and rhabdomyolysis (serious muscle damage potentially leading to kidney failure) | Use combination only when benefits outweigh risks; start with the lowest statin dose; monitor creatine kinase (CK) levels; stop immediately if muscle symptoms occur |
| Ciclosporin (immunosuppressant) | Both drugs can impair renal function; combination may cause severe and potentially irreversible kidney damage | Avoid concurrent use; if essential, monitor renal function very closely with frequent creatinine checks |
| Gemfibrozil (another fibrate) | Greatly increased risk of severe myopathy and rhabdomyolysis; no additional lipid benefit from combining two fibrates | Do not combine fenofibrate with gemfibrozil or any other fibrate under any circumstances |
| Ketoprofen (NSAID) | Cross-reactivity with photosensitivity reactions; increased risk of severe skin reactions from sunlight | Do not use fenofibrate if you have had phototoxic reactions with ketoprofen |
Minor Interactions
The following interactions may be clinically relevant but are generally manageable with appropriate monitoring:
| Medication | Effect of Interaction | Clinical Action |
|---|---|---|
| Glitazones (rosiglitazone, pioglitazone) | Cases of reversible, paradoxical decrease in HDL cholesterol have been reported when fenofibrate is combined with glitazones | Monitor HDL levels; discontinue combination if significant HDL decrease occurs |
| Bile acid sequestrants (cholestyramine, colestipol) | Can bind fenofibrate in the gastrointestinal tract, reducing its absorption | Take fenofibrate at least 1 hour before or 4–6 hours after bile acid sequestrants |
| Oral contraceptives | Estrogen-containing contraceptives can increase triglyceride levels, potentially counteracting fenofibrate’s effect | Monitor lipid levels; consider alternative contraception if triglycerides remain elevated |
When fenofibrate is prescribed together with a statin, the combination should only be used when the expected benefits clearly outweigh the potential risks. Your doctor will start with the lowest effective statin dose and monitor you closely for signs of muscle toxicity. If you develop any unexplained muscle pain, tenderness, weakness, or brown-coloured urine, stop both medications immediately and contact your doctor. The risk of rhabdomyolysis is highest with gemfibrozil–statin combinations (which are contraindicated), but fenofibrate–statin combinations also carry an elevated risk compared to statin monotherapy.
What Is the Correct Dosage of Lipanthyl?
Quick Answer: The recommended dose of Lipanthyl is one 200 mg capsule once daily, taken with a meal. Patients with kidney impairment may require a lower dose. Fenofibrate is not recommended for children or adolescents under 18 years.
Dosing of fenofibrate is relatively straightforward compared to some other lipid-modifying agents. However, the dose must be individualised based on the patient’s condition, kidney function, current treatment, and individual risk factors. Your doctor will determine the appropriate dose for you and monitor your response with regular blood lipid tests.
Adults
Standard Dose
Recommended dose: 1 capsule (200 mg fenofibrate) once daily.
Administration: Swallow the capsule whole with a glass of water. Do not open, crush, or chew the capsule.
Timing: Take with a meal. Food significantly enhances the absorption of fenofibrate — the medication is substantially less effective when taken on an empty stomach.
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Adults with normal kidney function | 200 mg once daily | Standard dose; take with a meal |
| Mild to moderate kidney impairment | 67–134 mg once daily | Dose reduction required; doctor will assess renal function and adjust accordingly. Lower-strength formulations may be needed |
| Severe kidney impairment (eGFR <15 mL/min) | Contraindicated | Do not use fenofibrate in severe renal impairment or dialysis patients |
| Elderly patients | 200 mg once daily (if kidney function is normal) | No specific dose adjustment for age alone; dose depends on renal function |
Children and Adolescents
Lipanthyl is not recommended for use in patients under 18 years of age. There is insufficient evidence regarding the safety and efficacy of fenofibrate in the paediatric population. If lipid management is required in children or adolescents, your doctor will consider alternative treatments and specialist referral.
Elderly Patients
No specific dose adjustment is required based on age alone. However, elderly patients are more likely to have impaired kidney function, and renal function should be assessed before starting treatment and periodically thereafter. The dose should be adjusted based on estimated glomerular filtration rate (eGFR). Elderly patients (over 70 years) are also at increased risk of muscle-related side effects, particularly when fenofibrate is combined with statins.
How to Take Lipanthyl
To ensure the best therapeutic result, follow these administration guidelines:
- With a meal: Always take the capsule during a meal. Food is essential for adequate absorption of fenofibrate from the gastrointestinal tract
- Swallow whole: Do not open, crush, or chew the capsule. The micronised formulation is designed for optimal drug release
- Consistency: Take at approximately the same time each day to maintain stable blood levels
- Lifestyle measures: Continue following a low-fat diet, exercising regularly, and managing your weight throughout treatment. Fenofibrate is a supplement to, not a replacement for, healthy lifestyle habits
- Long-term therapy: Abnormal lipid levels typically require ongoing treatment. Do not stop taking fenofibrate unless your doctor instructs you to do so, even if you feel well
Missed Dose
If you forget to take a dose, take it with your next meal at the normal time. Do not take a double dose to make up for a forgotten dose. Simply continue with your regular dosing schedule. If you are concerned about missed doses, speak with your doctor or pharmacist.
Overdose
If you take more Lipanthyl than prescribed, or if a child accidentally ingests the medication, contact your doctor, go to the nearest emergency department, or call your local poison control centre immediately. While there are no specific reports of fenofibrate overdose toxicity in the medical literature, any suspected overdose should be evaluated by a healthcare professional. Treatment is supportive and symptomatic, as there is no specific antidote for fenofibrate. Haemodialysis is not expected to be effective in removing fenofibrate due to its high protein binding.
What Are the Side Effects of Lipanthyl?
Quick Answer: The most common side effects of Lipanthyl are gastrointestinal symptoms (diarrhoea, abdominal pain, flatulence, nausea, vomiting) and elevated liver enzymes on blood tests. Serious but rare side effects include muscle damage (rhabdomyolysis), pancreatitis, blood clots, and severe skin reactions.
Like all medicines, Lipanthyl can cause side effects, although not everybody experiences them. Most side effects are mild to moderate and often resolve as the body adjusts to the medication. However, some side effects are serious and require immediate medical attention. If you experience any of the symptoms described below, especially those listed under “serious side effects,” stop taking the medication and contact your doctor immediately.
Allergic reactions (swelling of the face, lips, tongue, or throat causing difficulty breathing); unexplained muscle cramps, pain, tenderness, or weakness (possible signs of rhabdomyolysis); severe abdominal pain (possible pancreatitis); chest pain and shortness of breath (possible pulmonary embolism); pain, redness, or swelling in a leg (possible deep vein thrombosis); or yellowing of the skin and eyes (possible hepatitis).
Common Side Effects
Affects fewer than 1 in 10 patients
- Diarrhoea
- Abdominal pain or discomfort
- Flatulence (excess gas)
- Nausea
- Vomiting
- Elevated liver enzyme levels (transaminases) detected on blood tests
- Elevated homocysteine levels in the blood (high homocysteine has been associated with increased cardiovascular risk, although a direct causal relationship has not been established)
Uncommon Side Effects
Affects fewer than 1 in 100 patients
- Headache
- Gallstones (cholelithiasis)
- Decreased libido (reduced sexual desire)
- Skin rash, itching (pruritus), or red spots on the skin
- Elevated creatinine levels on blood tests (a substance excreted by the kidneys)
Rare Side Effects
Affects fewer than 1 in 1,000 patients
- Hair loss (alopecia)
- Elevated blood urea levels (detected on blood tests)
- Photosensitivity (increased sensitivity of the skin to sunlight, sunlamps, and tanning beds)
- Decreased haemoglobin levels and decreased white blood cell count (detected on blood tests)
Frequency Not Known
Reported post-marketing; frequency cannot be estimated
- Severe skin reactions with redness, peeling, and blistering resembling severe burns (Stevens-Johnson syndrome / toxic epidermal necrolysis)
- Interstitial lung disease (chronic lung problems causing breathing difficulty)
- Fatigue
- Muscle inflammation (myositis) and rhabdomyolysis (muscle breakdown potentially leading to kidney failure)
- Pancreatitis (inflammation of the pancreas)
- Deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Hepatitis (liver inflammation with jaundice)
Monitoring During Treatment
Your doctor will perform regular blood tests to monitor for potential side effects:
- Liver function tests: Transaminases (ALT/AST) should be checked before treatment, at 3 months, and then periodically. If levels exceed 3 times the upper limit of normal, fenofibrate should be discontinued
- Kidney function: Serum creatinine and eGFR should be monitored, particularly in patients with pre-existing kidney disease or risk factors
- Lipid panel: Triglycerides, total cholesterol, HDL, and LDL should be measured at approximately 3 months to assess treatment response. If there is no adequate improvement, your doctor may consider alternative or additional therapy
- Creatine kinase (CK): Measured if you report muscle symptoms, and at baseline if you have risk factors for myopathy
If you experience any side effects, including those not listed in this guide, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national medicines regulatory authority (for example, the EMA in Europe or the FDA in the United States). Reporting side effects helps to provide more information on the safety of this medicine.
How Should You Store Lipanthyl?
Quick Answer: Store Lipanthyl in the original packaging at room temperature, protected from moisture. Keep out of sight and reach of children. Do not use after the expiry date on the packaging.
Proper storage of Lipanthyl ensures that the medication maintains its potency and effectiveness throughout its shelf life:
- Packaging: Store in the original blister packaging to protect from moisture. Fenofibrate is moisture-sensitive, so avoid transferring capsules to other containers
- Temperature: No special temperature requirements. Store at normal room temperature (below 25°C / 77°F is generally recommended as a best practice)
- Moisture: Keep the blister packs dry. Do not store in the bathroom or near sources of humidity
- Children: Keep out of sight and reach of children at all times
- Expiry date: Do not use Lipanthyl after the expiry date stated on the carton and blister pack (after “EXP”). The expiry date refers to the last day of the stated month
- Disposal: Do not dispose of medications via household waste or wastewater. Return unused or expired capsules to your pharmacy for proper disposal. This helps protect the environment
What Does Lipanthyl Contain?
Quick Answer: Each Lipanthyl 200 mg capsule contains 200 mg of fenofibrate as the active ingredient, along with lactose monohydrate and other excipients in a hard gelatin capsule shell.
Active ingredient: Fenofibrate 200 mg per capsule. Fenofibrate is a lipid-modifying agent that is rapidly hydrolysed to its active metabolite, fenofibric acid, after oral administration. It is a white to off-white powder that is practically insoluble in water.
Excipients (inactive ingredients):
- Capsule contents: Lactose monohydrate, sodium lauryl sulfate, pregelatinised maize starch, crospovidone, and magnesium stearate
- Capsule shell: Gelatin, titanium dioxide (E171), red iron oxide (E172), and yellow iron oxide (E172)
Appearance: Lipanthyl 200 mg capsules are ochre-coloured (brownish-yellow) hard capsules.
Pack sizes: Available in blister packs of 28, 30, 90, or 100 capsules. Not all pack sizes may be available in every country.
Lipanthyl capsules contain lactose monohydrate as an excipient. If you have a known intolerance to lactose or other sugars, or if you have been diagnosed with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, speak with your doctor before taking this medication. The sodium content is less than 1 mmol (23 mg) per capsule, making it essentially sodium-free.
Brand Names and Availability
Fenofibrate is marketed under several brand names globally. The exact formulation, strength, and availability may vary by country:
- Lipanthyl: Marketed in several European countries including Sweden
- Lipantil Micro: Marketed in Ireland and the United Kingdom
- Thylip: An alternative fenofibrate brand
- Tricor: Commonly available in the United States and other markets (different formulation/strength)
- Fenoglide, Lipofen: Other fenofibrate formulations available in various countries
Different formulations of fenofibrate are not necessarily interchangeable due to differences in bioavailability. If your brand or formulation is changed, your doctor may need to monitor your lipid levels and adjust the dose.
Frequently Asked Questions About Lipanthyl
Lipanthyl (fenofibrate) is used to lower high levels of fats (lipids) in the blood, particularly triglycerides and cholesterol. It belongs to a group of medicines called fibrates. It is prescribed alongside a low-fat diet, exercise, and weight management to treat dyslipidaemia (abnormal blood fat levels). Fenofibrate may also be combined with statin therapy when statins alone do not provide adequate lipid control, particularly when both elevated triglycerides and low HDL cholesterol persist.
Yes, always take Lipanthyl with a meal. Food significantly improves the absorption of fenofibrate from the gastrointestinal tract. If taken on an empty stomach, the medication will not be absorbed as effectively, reducing its therapeutic benefit. Swallow the capsule whole with a glass of water during your meal — do not open, crush, or chew it. The timing of the meal (breakfast, lunch, or dinner) does not matter, but consistency in timing helps maintain stable blood levels.
Yes, fenofibrate can be prescribed alongside a statin in certain clinical situations, particularly when a statin alone does not adequately control both LDL cholesterol and triglyceride levels. However, this combination increases the risk of muscle-related side effects, including myopathy and rhabdomyolysis (serious muscle breakdown that can damage the kidneys). Your doctor will carefully weigh the benefits against the risks, start with the lowest effective statin dose, and monitor you closely. Important: Fenofibrate should never be combined with gemfibrozil (another fibrate), as this combination carries an unacceptably high risk of rhabdomyolysis.
The most common side effects (affecting fewer than 1 in 10 patients) are gastrointestinal: diarrhoea, abdominal pain, flatulence, nausea, and vomiting. Elevated liver enzyme levels may also be detected on blood tests. These effects are usually mild and often improve over time. Serious but rare side effects include muscle damage (rhabdomyolysis), pancreatitis, blood clots, and severe skin reactions. If you experience unexplained muscle pain or weakness, stop taking the medication and contact your doctor immediately.
No, fenofibrate must not be taken during pregnancy or breastfeeding. There is insufficient data on its safety in pregnant women, and animal studies have shown potential risks to the developing foetus. It is also unknown whether fenofibrate passes into breast milk. If you are pregnant, planning to become pregnant, or breastfeeding, inform your doctor immediately so that alternative lipid management strategies can be considered.
Fenofibrate typically begins to reduce triglyceride levels within 1–2 weeks of starting treatment. However, the full therapeutic effect may take 4–8 weeks. Your doctor will typically order a lipid panel after approximately 3 months of treatment to assess your response. If there is no adequate improvement in lipid levels despite optimal dosing and lifestyle modifications, your doctor may re-evaluate your treatment plan. It is important to continue following a low-fat diet and exercising regularly throughout treatment, as fenofibrate is most effective when combined with lifestyle measures.
References
This article is based on peer-reviewed medical literature, international clinical guidelines, and official drug information resources:
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003
- Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet. 2005;366(9500):1849-1861. doi:10.1016/S0140-6736(05)67667-2
- ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574. doi:10.1056/NEJMoa1001282
- European Medicines Agency (EMA). Fenofibrate – Summary of Product Characteristics. EMA, 2024.
- British National Formulary (BNF). Fenofibrate. NICE, 2025. Available at: bnf.nice.org.uk
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. WHO, 2023.
- Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088-2093. doi:10.1161/01.CIR.98.19.2088
- Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1. J Clin Lipidol. 2015;9(2):129-169. doi:10.1016/j.jacl.2015.02.003
Editorial Team
This article has been written, reviewed, and approved by the iMedic Medical Editorial Team in accordance with international medical guidelines (ESC/EAS, AHA/ACC, WHO, BNF).
Licensed physicians with specialisation in cardiology, internal medicine, and clinical pharmacology. All content follows the GRADE evidence framework.
Independent review by board-certified cardiologists and lipid specialists ensuring accuracy, completeness, and adherence to current best practices and guidelines.
Evidence level: Level 1A — based on systematic reviews and meta-analyses of randomised controlled trials, including the FIELD and ACCORD studies.
Conflicts of interest: None. iMedic receives no commercial funding and has no pharmaceutical industry affiliations.
Published: | Last reviewed: